Rankings
▼
Calendar
URGN Q4 2019 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena
URGN
UroGen Pharma Ltd.
$918M
Q4 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$40M
Net Income
-$39M
EPS (Diluted)
$-1.84
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$26M
Free Cash Flow
-$26M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$202M
Total Liabilities
$22M
Stockholders' Equity
$180M
Cash & Equivalents
$50M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$40M
-$24M
-65.9%
Net Income
-$39M
-$24M
-64.3%
← FY 2019
All Quarters
Q1 2020 →